Enliven Therapeutics Q1 net loss $22.7M; ELVN-001 Phase 1 shows 44% MMR at 12 weeks

Enliven Therapeutics, Inc.

2024-Q1 EPS reported -$0.54

Net loss of $22.7M for Q1 2024 vs $14.7M in Q1 2023; cash, equivalents & marketable securities $320.5M.
ELVN-001 Phase 1 proof-of-concept: 44% (7/16) cumulative MMR rate by week 12 in response-evaluable CML patients.
Entered $90M PIPE financing from new/existing investors; expected cash runway into late 2026.
Appointed Dr. Lori Kunkel to Board of Directors.
Activated first site for ELVN-002 combo trial with trastuzumab in HER2+ cancers; first dosing expected Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Enliven Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $22.7 million.

Period: first quarter ended March 31, 2024
Net income: $22.7 million
Result: reported results

Exact text from the filing

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059544

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.